Shanghai Shyndec Pharmaceutical (600420.SH): Famotidine Injection passes generic drug quality and efficacy consistency evaluation.

Shanghai Shyndec Pharmaceutical (600420.SH) announced that its wholly-owned subsidiary Guoyao Group Rongsheng Pharmaceutical Co., Ltd. (hereinafter referred to as Guoyao Rongsheng) recently received the "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration, approving the consistency evaluation of the quality and efficacy of famotidine injection as a generic drug. Famotidine is a histamine H2 receptor antagonist used for upper gastrointestinal bleeding caused by peptic ulcers, as well as for mucosal ulcer bleeding in the stomach and duodenum caused by various reasons other than tumors and esophageal and gastric varices.